A New Chapter for Oral Precision Therapies in Thyroid Cancer: RET Inhibitors - a podcast by ReachMD

CME credits: 1.00

Valid until: 29-12-2022

Claim your CME credit at https://reachmd.com/programs/cme/a-new-chapter-for-oral-precision-therapies-in-thyroid-cancer-ret-inhibitors/13137/

Although multi-kinase inhibitors (MKIs) have been the standard of care for the treatment of thyroid cancer, they produce excessive “off-target” clinical adverse effects and toxicity that limit their use in some patients, leading to drug discontinuation or dose reduction. The introduction of RET inhibitors into the thyroid cancer treatment landscape offers novel, efficacious therapies for patients who previously had limited treatment options.

This online, on-demand educational activity will review RET alterations in thyroid cancer, molecular diagnostic testing, and recent and emerging clinical data on novel therapies targeting RET-altered or RET-driven thyroid cancer. A Virtual Case Clinic Video Exercise will highlight and demonstrate the translation of these RET-targeted therapies into real-world clinical practice for the treatment of patients with thyroid cancer.

Further episodes of ReachMD CME

Further podcasts by ReachMD

Website of ReachMD